At what age and frequency should a woman have a Pap (Papanicolau) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cervical Cancer Screening: Age and Frequency Guidelines

Direct Recommendation

Women should begin Pap testing at age 21 years and continue screening every 3 years until age 29, then transition to either co-testing (Pap plus HPV) every 5 years (preferred) or Pap alone every 3 years from ages 30-65, and discontinue screening after age 65 if adequately screened. 1, 2


Age-Specific Screening Algorithm

Ages <21 Years

  • Do not screen, regardless of sexual activity or age of sexual debut 2
  • Cervical cancer is extremely rare in this age group, and screening leads to unnecessary interventions 3

Ages 21-29 Years

  • Screen every 3 years with Pap test alone 1, 2
  • Do NOT use HPV testing in this age group for routine screening 2
  • After first normal result, continue every 3 years (not annually) 1, 2

Ages 30-65 Years

  • Preferred: Co-testing (Pap + HPV) every 5 years 1, 2
  • Acceptable: Pap test alone every 3 years 1, 2
  • The 5-year interval with co-testing is supported by increased sensitivity of the combined approach 2

Ages >65 Years

  • Stop screening if adequately screened with normal results 1, 2, 4
  • Adequate screening defined as: ≥3 consecutive negative Pap tests OR ≥2 consecutive negative co-tests within the last 10 years, with most recent test in last 5 years 1, 4
  • Once stopped, do not resume screening even with new sexual partners 4

Special Populations Requiring Modified Screening

Continue Screening Beyond Age 65 If:

  • History of CIN2, CIN3, or adenocarcinoma in situ: Continue routine screening for at least 20 years after treatment, even past age 65 4, 5
  • Inadequate prior screening: Cannot document adequate negative screening history 4
  • High-risk factors: HIV/immunosuppression, multiple sexual partners, smoking, pessary use 4, 5
  • Never screened: Perform at least 2 negative tests one year apart regardless of age 2, 4

Discontinue Screening If:

  • Total hysterectomy with cervix removal for benign reasons 1, 2, 4
  • Exception: Continue if hysterectomy was for cervical cancer or precursors 4

Critical Pitfalls to Avoid

Over-Screening

  • Annual Pap testing is NOT recommended for any age group 1, 2
  • Despite guidelines, research shows 36% of women still receive annual screening when only triennial is needed 6
  • Over-screening increases costs and harms (false positives, unnecessary procedures) without meaningful mortality benefit 2
  • Only 19% of physicians correctly recommend 3-year intervals with co-testing, versus 31.8% with Pap alone 7

Under-Screening High-Risk Groups

  • Women aged 21-29 years show concerning trends: 9% report never being screened 3
  • Asian women (31.4%), LGBQ+ individuals (32.0%), rural residents (26.2%), and uninsured women (41.7%) have significantly higher rates of overdue screening 8
  • Recent immigrants and those without usual healthcare source have lower screening rates 9

Premature Discontinuation

  • 14 million US women aged 21-65 are not up-to-date with screening 9
  • The most common barrier is lack of knowledge (47-64% across demographic groups), not access 8
  • Provider failure to recommend screening increased from 5.9% to 12.0% between 2005-2019 8

Evidence Quality and Nuances

The American Cancer Society guidelines 1 published in CA: A Cancer Journal for Clinicians (2019) represent the highest quality, most recent consensus recommendations and are consistent across multiple guideline organizations 2. The 3-year screening interval is supported by strong evidence showing that annual versus triennial screening improves effectiveness by less than 5% 2.

Research data 9, 8 reveal concerning declines in screening rates from 2005-2019, with the proportion of women not up-to-date increasing from 14.4% to 23.0%, emphasizing the need for improved patient and provider education about guideline-concordant intervals.

The mortality benefit of cervical cancer screening is well-established, but only when screening occurs at appropriate intervals in the appropriate age groups 4. In well-screened women over 65, CIN2+ prevalence is extremely low, and the ratio of colposcopies to life-years gained becomes unfavorable 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cervical Cancer Screening Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cervical cancer screening among women aged 18-30 years - United States, 2000-2010.

MMWR. Morbidity and mortality weekly report, 2013

Guideline

Cessation of Pap Smear Screening in Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening Guidelines for Women with Abnormal Pap History

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pap screening in a U.S. health plan.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2004

Related Questions

What are the screening recommendations for cervical cancer using a Pap (Papanicolau) smear?
What are the recommended guidelines for Pap (Papanicolau) tests and Human Papillomavirus (HPV) testing for cervical cancer screening?
What are the current guidelines for Pap (Papanicolau) smear screening?
What are the guidelines for screening pap smear?
How often is a Pap (Papanicolau) test done?
What is the best course of action for a patient with Hypertension (HTA), Dyslipidemia (DLP), Type 2 Diabetes Mellitus (DM 2), Hypothyroidism, and knee/hip osteoarthritis, taking Atorvastatina (Atorvastatin) 20mg, Hidroclorotiazida (Hydrochlorothiazide) 50mg, Metformina (Metformin) 850mg, Enalapril (Enalapril) 10mg, and Levotiroxina (Levothyroxine) 100mcg, who has poor adherence to treatment, and is experiencing worsening symptoms of nausea, vomiting, dysuria, eructation, headache, fever, shortness of breath, chest pain, and fatigue after starting Levofloxacino (Levofloxacin) 750mg daily for a urinary tract infection?
What is the management approach for a patient with positive tissue transglutaminase (tTG) antibodies but a negative biopsy for celiac disease?
What medications are effective for treating stress eating, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac) or sertraline (Zoloft)?
What happens if the Left Internal Mammary Artery (LIMA) graft is not ligated after a Coronary Artery Bypass Grafting (CABG) surgery?
What is the best initial approach for a 28-week pregnant patient with mild shortness of breath (SOB) on exertion and a normal exam?
What is the Maxillomandibular Advancement (MMA) procedure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.